CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: A meta-analysis of 51 studies

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 80, Issue 9, 2009, Pages 966-975

  Mitchell, A J ^a  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOPROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; HUMAN; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; SYSTEMATIC REVIEW; AGED; CEREBROSPINAL FLUID; COGNITIVE DEFECT; META ANALYSIS; PHOSPHORYLATION; PREDICTION AND FORECASTING; PSYCHOLOGICAL ASPECT; REVIEW;

AGED; ALZHEIMER DISEASE; COGNITION DISORDERS; HUMANS; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TAU PROTEINS;

EID: 69449084273     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.167791     Document Type: Article

References (77)

1. Blennow K, Hampel H. Cerebrospinal fluid markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-613
2. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308 (Pubitemid 29120227)
3. Andreasen N, Blennow K. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg 2005;107:165-173 (Pubitemid 40502220)
4. de Leon Mj, Desanti S, Zinkowski R, et al. MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med 2004;256:205-223 (Pubitemid 39222990)
5. Frank RA, Galasko D, Hampel H, et al. Biological markers for therapeutic trials in Alzheimer's disease Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging 2003;23:521-536
6. Waldemar G, Dubois B, Emre M, et al. EFNS TASK FORCE/CME ARTICLE Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007;14:e1-26. (Pubitemid 46088015)
7. Braak H, Braak E. Aspects of cortical destruction in Alzheimer's disease. In: Hyman BT, Duyckaerts C, Christen Y, eds. Connections, cognition and Alzheimer's disease. Berlin: Springer-Verlag, 1997:1-16.
8. Petersen RC, Parisi JE, Dickson DW, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006;63:665-672
9. Hampel H, Mitchell A, Blennow K, et al. Core biological marker candidates of Alzheimer's disease - Perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm 2004;111:247-272 (Pubitemid 38316604)
10. Mitchell A, Brindle N. CSF phosphorylated tau - does it constitute an accurate biological test for Alzheimer's disease? Int J Geriatr Psychiatry 2003;18:407-411
11. de Leon MJ, DeSanti S, Zinkowski R, et al. MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med 2004;256:205-223 (Pubitemid 39222990)
12. Andreasen N, Sjogren M, Blennow K. CSF markers for Alzheimer's disease: Total Tau, phospho-tau and A beta 42. World J Biol Psychiatry 2003;4:147-155
13. Blennow K, Wallin A, Agren H, et al. Tau protein in cerebrospinal fluid - A biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26:231-245
14. Rosso SM, Van Herpen E, Pijnenburg YAL, et al. Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to p301L and G272V tau mutations. Arch Neurol 2003;60:1209-1213 (Pubitemid 37099625)
15. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of tau proteins in normal and Alzheimers-disease cerebrospinal-fluid with a sensitive sandwich enzyme-linked- immunosorbent-assay. J Neurochem 1993;61:1828-1834 (Pubitemid 23317209)
16. Trojanowski JQ, Lee VMY. The role of tau in Alzheimer's disease. Med Clin North Am 2002;86:615.
17. Bouwman FH, van der Flier WM, Scheltens P. Can lumbar puncture help to identify patients with incipient Alzheimer's disease? Nat Clin Pract Neurol 2006;2:530-531
18. Hansson O, Buchhave P, Zetterberg H, et al. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 2009;30:165-173
19. Pai M, McCulloch M, Enanoria W, et al. Systematic reviews of diagnostic test evaluations: what's behind the scenes? Evid Based Med 2004;9:101-103
20. Bossuyt PM, Reitsma JB, Bruns DE, et al, for the STARD steering group. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003;326:41-44
21. Deeks JJ. Systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001;323:157-162
22. Mitchell AJ. A meta-analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment. J Psychiatr Res 2009;43:411-431
23. Mitchell AJ, McGlinchey JB, Young D, et al. Accuracy of specific symptoms in the diagnosis of major depressive disorder in psychiatric outpatients - Data from the MIDAS Project. Psychol Med 2009;39:1107-1116
24. Parnetti L, Amici S, Lanari A, et al. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurol Sci 2002;23(Suppl 2):S95-6. (Pubitemid 35355793)
25. Papassotiropoulos A, Streffer JR, Tsolaki M, et al. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol 2003;60:29-35. (Pubitemid 36078105)
26. Ishiguro K, Ohno H, Arai H, et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett 1999;270:91-94 (Pubitemid 29333843)
27. Hu YY, He S-S, Wang X-C, et al. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett 2002;320:156-160 (Pubitemid 34164438)
28. Blennow K. Tau, phospho-tau and Ab42 in cerebrospinal fluid in Alzheimer's disease. Neurobiol Aging 2002;23(Suppl 1):1396.
29. de Leon MJ, Segal S, Tarshish CY, et al Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett 2002;333:183-186 (Pubitemid 35335773)
30. Hu YY, He SS, Wang XC, et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients - An ultrasensitive bienzymesubstrate- recycle enzyme-linked immunosorbent assay. Am J Pathol 2002;160:1269-1278
31. Wahlund L-O, Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 2003;339:99-102. (Pubitemid 36254786)
32. Itoh N, Arai H, Urakami K, et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 2001;50:150-156 (Pubitemid 32738138)
33. Kohnken R, Buerger K, Zinkowski R, et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 2000;287:187-190 (Pubitemid 30339380)
34. Buerger K, Zinkowski R, Teipel SJ, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002;59:1267-1272 (Pubitemid 34856379)
35. Buerger K, Zinkowski R, Teipel SJ, et al. Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. Am J Psychiatry 2003;160:376-379 (Pubitemid 41110469)
36. Vanmechelen E, Van Kerschaver E, Blennow K, et al. CSF-Phospho-tau (181P) as a promising marker for discriminating Alzheimer's disease from dementia with Lewy bodies. In: Iqbal K, Sisodia SS, Winblad B, eds. Alzheimer's disease: advances in etiology, pathogenesis and therapeutics. Chichester: John Wiley and Sons, 2001:285-291
37. Parnetti L, Lanari A, Amici S, et al. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Neurol Sci 2001;22:77-78 (Pubitemid 33622091)
38. Sjögren M, Davidsson P, Tullberg M, et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;70:624-630 (Pubitemid 32397998)
39. Nägga K, Gottfries J, Blennow K, et al. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Dis 2002;14:183-190
40. Sjögren M, Davidson P, Wallin A, et al. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement Geriatr Cogn Dis 2002;13:112-118 (Pubitemid 34161156)
41. Hampel H, Buerger K, Zinkowski R, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 2004;61:95-102. (Pubitemid 38044645)
42. Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide(42). Arch Neurol 2003;60:1202-1206
43. Rosso SM, van Herpen E, Pijnenburg YAL. Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations. Arch Neurol 2003;60:1209-1213
44. Riemenschneider M, Wagenpfeil S, Vanderstichele H, et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry 2003;8:343-347 (Pubitemid 36712928)
45. Ibach B, Binder H, Dragon M, et al. Cerebrospinal fluid tau and -amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiol Aging 2006;27:1202-1211 (Pubitemid 44067302)
46. Kapaki EN, Paraskevas GP, Tzerakis NG, et al. Cerebrospinal fluid tau, phosphotau181 and β-amyloid1242 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease. Eur J Neurol 2007;14:168-173
47. Saez-Valero J, Fodero LR, Sjogren M, et al. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease. J Neurosci Res 2003;72:520-526 (Pubitemid 36523426)
48. Schoonenboom NSM, Pijnenburg YAL, Mulder C, et al. Amyloid B (1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 2004;62:1580-1584 (Pubitemid 38608199)
49. Wada-Isoe K, Kitayama M, Nakaso K, et al. Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study. J Neurol Sci 2007;260:33-37 (Pubitemid 47212190)
50. Ingelsson M, Blom E, Zetterberg H, et al. CSF Tau levels and APOEe4 carriership predict the progression of mild cognitive impairment to Alzheimer's disease. Alzheimers Dement J Alzheimers Assoc 2008;4:T540.
51. Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49-52. (Pubitemid 30224621)
52. Schönknecht P, Pantel J, Hunt A, et al. Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease. Neurosci Lett 2003;339:172-174 (Pubitemid 36254803)
53. Engelborghs S, Koopman K, Bastard NL, et al. Improved discrimination of Alzheimer's disease from other dementias using cerebrospinal fluid P-Tau181p. Alzheimers Dement J Alzheimers Assoc 2008;4:T537.
54. Andreasen N, Vanmechelen E, Vanderstichele H, et al. CSF levels of total tau, phospho tau and Ab42 predicts development of Alzheimer disease in patients with mild cognitive impairment. Acta Neurol Scand 2003;107(Suppl 179):47-51.
55. Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-234 (Pubitemid 43238346)
56. Urakami K. Mild cognitive impairment - biological diagnostic markers for early stages of Alzheimer's disease. Psychogeriatrics 2006;6:S26-9. (Pubitemid 44889421)
57. Arai H, Ishiguro K, Ohno H, et al. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol 2000;166:201-203 (Pubitemid 30824307)
58. de Leon MJ, DeSanti S, Zinkowski R, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006;27:394-401. (Pubitemid 43185324)
59. Buerger K, Teipel SJ, Zinkowski R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 2002;59:627-629 (Pubitemid 34920005)
60. Fellgiebel A, Scheurich A, Bartenstein P, et al. FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment. psychiatry research. Neuroimaging 2007;155:167-171 (Pubitemid 46874913)
61. Herukka SK, Hallikainen M, Soininen H, et al. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005;64:1294-1297 (Pubitemid 40490543)
62. Ewers M, Buerger K, Teipel SJ, et al. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 2007;69:2205-2212 (Pubitemid 350294675)
63. Brys M, Pirraglia E, Rich K, et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 2009;30:682-690
64. Feldman H, Levy AR, Hsiung GY, et al. A Canadian cohort study of cognitive impairment and related dementias (ACCORD): Study methods and baseline results. Neuroepidemiology 2003;22:265-274 (Pubitemid 36993907)
65. Ólafsdóttir M, Skoog I, Marcusson J. Detection of dementia in primary care: The Linköping Study. Dement Geriatr Cogn Disord 2000;11:223-229 (Pubitemid 30416028)
66. Luck T, Riedel-Heller SG, Kaduszkiewicz H, et al, AgeCoDe group. Mild cognitive impairment in general practice: age-specific prevalence and correlate results from the German study on ageing, cognition and dementia in primary care patients (AgeCoDe). Dement Geriatr Cogn Disord 2007;24:307-316
67. Hampel H, Teipel SJ, Fuchsberger T, et al. Value of CSF B-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 2004;9:705-710 (Pubitemid 38932175)
68. Diniz BSO, Pinto Jr JA, Forlenza OV. Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry 2008;9:172-182
69. Blennow K, Hampel H. Cerebrospinal fluid markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-613
70. Sunderland T, Linker G, Mirza N, et al. Decreased b-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer's disease. JAMA 2003;289:2094-2103 (Pubitemid 37430211)
71. Peskind ER, Li G, Quinn JF, et al. Cerebrospinal fluid biomarkers distinguish mild Alzheimer's disease and mild cognitive impairment from cognitively healthy aging. Alzheimers Dement J Alzheimers Assoc 2008;4:T544.
72. Consensus Report of the Working Group on Molecular and Biochemical Markers of Alzheimer's disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998;19:109-116
73. Clark CM, Sharon X, Chittams J, et al. Cerebrospinal fluid tau and b-amyloid. How well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 2003;60:1696-1702
74. Herukka S-K, Tapiola T, Hallikainen M, et al. CSF Aβ42, tau and phosphorylated tau are biomarkers for Alzheimer's disease neuropathology and predict development of Alzheimer's disease in patients with mild cognitive impairment. Alzheimer Dement 2008;4:T539.
75. Grossman M, Farmer J, Leight S, et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol 2005;57:721-729 (Pubitemid 40628861)
76. Tapiola T, Pirttila T, Mehta PD, et al. Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease. Neurobiol Aging 2000;21:735-740 (Pubitemid 30759085)
77. Frank RA, Galasko D, Hampel H, et al. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging 2003;24:521-536